Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab...
37 KB (3,213 words) - 00:29, 30 September 2024
CSCC who are not candidates for curative surgery or curative radiation. Dostarlimab (Jemperli) – was developed by GlaxoSmithKline and was first approved...
35 KB (3,450 words) - 03:38, 30 September 2024
stage II or III rectal adenocarcinoma were administered single-agent dostarlimab, an anti–PD-1 monoclonal antibody, every three weeks for six months....
146 KB (15,930 words) - 20:53, 7 November 2024
inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
80 KB (7,412 words) - 02:30, 16 October 2024
inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
9 KB (603 words) - 00:28, 30 September 2024
inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
46 KB (4,813 words) - 05:06, 15 October 2024
inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
9 KB (460 words) - 00:28, 30 September 2024
for breast and ovarian cancer. TSR-042 TSR-022 Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults...
5 KB (364 words) - 23:58, 12 September 2024
inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
13 KB (1,060 words) - 00:29, 30 September 2024
hormone replacement therapy after treatment for endometrial cancer. Dostarlimab has been approved by the FDA for therapy of endometrial cancer with specific...
105 KB (10,821 words) - 12:23, 31 July 2024
Regeneron PD-1 2018 squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer Dostarlimab Jemperli Tesaro PD-1 2021 endometrial cancer...
21 KB (2,093 words) - 02:41, 1 September 2024
(eptifibatide) (Europe) Jalyn (dutasteride-tamsulosin hydrochloride) Jemperli (dostarlimab) Jesduvroq (daprodustat) Lacipil (lacidipine) Lamictal (lamotrigine)...
7 KB (628 words) - 18:58, 27 December 2023
inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
15 KB (1,447 words) - 00:31, 30 September 2024
inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
28 KB (2,721 words) - 04:14, 1 October 2024
mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin...
12 KB (821 words) - 02:57, 12 October 2024
Durvalumab L01FF04 Avelumab L01FF05 Atezolizumab L01FF06 Cemiplimab L01FF07 Dostarlimab L01FF08 Prolgolimab L01FF09 Tislelizumab L01FF10 Retifanlimab L01FF11...
12 KB (877 words) - 15:36, 25 January 2024
approved by the FDA for cancer include: Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab...
48 KB (4,964 words) - 04:26, 20 October 2024
inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
43 KB (4,183 words) - 04:17, 1 October 2024
inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand...
2 KB (160 words) - 19:37, 6 November 2024
lung disease Rilonacept Kiniksa Pharmaceuticals recurrent pericarditis Dostarlimab GSK mismatch repair deficient recurrent or advanced endometrial cancer...
34 KB (180 words) - 17:05, 14 October 2024
humanized Amyloid beta Y Alzheimer's disease Dorlimomab aritox F(ab')2 mouse Dostarlimab Jemperli mab humanized PCDP1 Y endometrial cancer Drozitumab mab human...
137 KB (4,083 words) - 21:25, 19 October 2024
Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412§ Immune activation: Dostarlimab Other: Ibalizumab Chimeric + humanized Otelixizumab Rozanolixizumab Sutimlimab...
38 KB (4,316 words) - 10:24, 26 August 2024
mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin...
12 KB (758 words) - 23:46, 14 March 2024
Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412§ Immune activation: Dostarlimab Other: Ibalizumab Chimeric + humanized Otelixizumab Rozanolixizumab Sutimlimab...
2 KB (87 words) - 01:28, 30 May 2023
(ETTs) are resistant to chemotherapy, but an immunotherapy drug called dostarlimab treats gestational trophoblastic neoplasia. ETT is a form of GTN. Stage...
3 KB (243 words) - 15:24, 29 October 2023